683 related articles for article (PubMed ID: 19934334)
1. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
2. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
Rosenblum MG; Shawver LK; Marks JW; Brink J; Cheung L; Langton-Webster B
Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
[TBL] [Abstract][Full Text] [Related]
3. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
Cao Y; Marks JD; Huang Q; Rudnick SI; Xiong C; Hittelman WN; Wen X; Marks JW; Cheung LH; Boland K; Li C; Adams GP; Rosenblum MG
Mol Cancer Ther; 2012 Jan; 11(1):143-53. PubMed ID: 22090420
[TBL] [Abstract][Full Text] [Related]
4. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
[TBL] [Abstract][Full Text] [Related]
5. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence.
Wang F; Ren J; Qiu XC; Wang LF; Zhu Q; Zhang YQ; Huan Y; Meng YL; Yao LB; Chen SY; Xu YM; Yang AG
Clin Cancer Res; 2010 Apr; 16(8):2284-94. PubMed ID: 20371697
[TBL] [Abstract][Full Text] [Related]
6. Cell-targeting fusion constructs containing recombinant gelonin.
Lyu MA; Cao YJ; Mohamedali KA; Rosenblum MG
Methods Enzymol; 2012; 502():167-214. PubMed ID: 22208986
[TBL] [Abstract][Full Text] [Related]
7. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
9. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
10. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin.
Rosenblum MG; Cheung LH; Liu Y; Marks JW
Cancer Res; 2003 Jul; 63(14):3995-4002. PubMed ID: 12873997
[TBL] [Abstract][Full Text] [Related]
11. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
[TBL] [Abstract][Full Text] [Related]
12. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin.
Cizeau J; Grenkow DM; Brown JG; Entwistle J; MacDonald GC
J Immunother; 2009; 32(6):574-84. PubMed ID: 19483652
[TBL] [Abstract][Full Text] [Related]
13. Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo.
Shi M; Zhang L; Gu HT; Jiang FQ; Qian L; Yu M; Chen GJ; Luo Q; Shen BF; Guo N
Acta Pharmacol Sin; 2007 Oct; 28(10):1611-20. PubMed ID: 17883948
[TBL] [Abstract][Full Text] [Related]
14. A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma.
Wang LF; Zhou Y; Xu YM; Qiu XC; Zhou BG; Wang F; Long H; Chen X; Yang TT; Ma BA; Fan QY; Yang AG
Cancer Invest; 2009 Aug; 27(7):774-80. PubMed ID: 19488908
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
16. The effect of direct translocation across endosomes on the cytotoxicity of the recombinant protein e23sFv-Fdt-casp6 to HER2 positive gastric cancer cells.
Ren JL; Meng YL; Hu B; Jia LT; Zhang R; Xu YM; Xie QS; Zhang YQ; Jin BQ; Chen SY; Wang T; Yang AG
Biomaterials; 2011 Oct; 32(30):7641-50. PubMed ID: 21767874
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
Mohamedali KA; Poblenz AT; Sikes CR; Navone NM; Thorpe PE; Darnay BG; Rosenblum MG
Cancer Res; 2006 Nov; 66(22):10919-28. PubMed ID: 17108129
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
19. Photochemical activation of the recombinant HER2-targeted fusion toxin MH3-B1/rGel; Impact of HER2 expression on treatment outcome.
Bull-Hansen B; Cao Y; Berg K; Skarpen E; Rosenblum MG; Weyergang A
J Control Release; 2014 May; 182():58-66. PubMed ID: 24637464
[TBL] [Abstract][Full Text] [Related]
20. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
Todhunter DA; Hall WA; Rustamzadeh E; Shu Y; Doumbia SO; Vallera DA
Protein Eng Des Sel; 2004 Feb; 17(2):157-64. PubMed ID: 15047912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
